The effect of silencing NKG2D through RNA interference on receptor functions in interleukin-2-activated human natural killer cells

Haematologica

Volumn 91, Issue 11, 2006, Pages 1538-1541

  Baeriswyl, Vanessa ^a   Wodnar Filipowicz, Aleksandra ^a   Kalberer, Christian P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Activating receptor; Cytotoxicity; Innate immunity; Interferon; siRNA

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; IMMUNOLOGIC FACTOR; INTERLEUKIN 2; SMALL INTERFERING RNA;

ARTICLE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INNATE IMMUNITY; LEUKEMIA; NATURAL KILLER CELL; NORMAL HUMAN; RNA INTERFERENCE;

CELLS, CULTURED; GENE SILENCING; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; RECEPTORS, IMMUNOLOGIC; RNA INTERFERENCE;

EID: 33750959905     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-90:
2. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-9.
3. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-66.
4. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
5. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 2004;172:7335-40.
6. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-96.
7. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 2005;19:2215-22.
8. + cells. Blood 2004;103:4511-3.
9. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-5.
10. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102:1869-71.
11. + cells. Blood 2003;102:127-35.
12. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005;105:3615-22.
13. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-32.
14. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159-66.
15. + T Cells and NK Cells. J Immunol 2005;175:7819-28.
16. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-37.
17. Wiemann K, Mittrucker HW, Feger U, Weite SA, Yokoyama WM, Spies T, et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005;175:720-9.
18. Miller JS, Soignier Y, Fanoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
19. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004;18:1835-8.